Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fenfluramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 4/20 | 0.97 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.62 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.97 |
| ▸ | HTR2A | P28223 | 4/20 | 0.97 |
| ▸ | HTR2B | P41595 | 4/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.97 |
| ▸ | DRD3 | P35462 | 4/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenfluramine SCHEMBL16215 | 0.98 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Fenfluramine SCHEMBL29447403 | 0.98 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Dexfenfluramine SCHEMBL15669714 | 0.98 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Dexfenfluramine SCHEMBL16706 | 0.98 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Levofenfluramine SCHEMBL162006 | 0.98 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Dexfenfluramine SCHEMBL29499611 | 0.98 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Levofenfluramine SCHEMBL29882976 | 0.98 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Levofenfluramine SCHEMBL30951308 | 0.97 | SLC6A4 (0.97) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Fenfluramine SCHEMBL39491 | 0.97 | SLC6A4 (0.97) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Fenfluramine SCHEMBL9080932 | 0.97 | SLC6A4 (0.97) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299064-A1 | METHOD OF TREATING PATIENTS WITH LENNOX-GASTAUT SYNDROME | ZOGENIX INTERNATIONAL LIMITED (GB) | 2021-09-30 | — | — | US | disclosed |
| WO-2021156437-A1 | FENFLURAMINE FOR USE IN TREATING PATIENTS WITH LENNOX-GASTAUT SYNDROME | ZOGENIX INTERNATIONAL LIMITED (GB) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299064-A1 | METHOD OF TREATING PATIENTS WITH LENNOX-GASTAUT SYNDROME | EPM2A, GABRA5, GABRG3 | SIGMAR1 3895/4885HTR2C 112/4885HTR1D 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.